Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Cord (and medulla) 47.4 Gy (5 cc) and 52.8 Gy (0.035 cc); <b>Cord contouring instructions<b>: "Entire bony canal including at least 10 cm superior and inferior to PTV." Brainstem (not medulla) 52 Gy (5 cc) and 60 Gy (0.035 cc); <b>Brainstem (not medulla) contouring instructions<b>: "Superiorly from incisura, midbrain and pons only, 1 structure."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Brachial plexus 62 Gy (3 cc) and 66 Gy (0.035 cc). <b>Contouring instructions<b>: "Each side separately from the spinal nerves exiting the neuroforamina from around C5 to T2 to include only the major trunks of the brachial plexus using the subclavian and axillary vessels as a surrogate for identifying its location extending proximally at the bifurcation of the brachiocephalic trunk into the jugular/subclavian veins (o
Per the post-HyTEC brachial plexus paper <ll>Milano IJROBP '23!https://pubmed.ncbi.nlm.nih.gov/36682981/<ll>: "When delineating the brachial plexus, structures that assist with image segmentation are first identified, including the C4-5 and T1-2 neural foramina (best identified in the sagittal plane), the anterior and middle scalene muscles, and the subclavian neurovascular bundle. Next, the C5-T1 ventral rami are delineated, continuing caudally and laterally between the middle and anterior scal
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Brachial plexus 62 Gy (3 cc) and 66 Gy (0.035 cc). <b>Contouring instructions<b>: "Each side separately from the spinal nerves exiting the neuroforamina from around C5 to T2 to include only the major trunks of the brachial plexus using the subclavian and axillary vessels as a surrogate for identifying its location extending proximally at the bifurcation of the brachiocephalic trunk into the jugular/subclavian veins (o
Per the post-HyTEC brachial plexus paper <ll>Milano IJROBP '23!https://pubmed.ncbi.nlm.nih.gov/36682981/<ll>: "When delineating the brachial plexus, structures that assist with image segmentation are first identified, including the C4-5 and T1-2 neural foramina (best identified in the sagittal plane), the anterior and middle scalene muscles, and the subclavian neurovascular bundle. Next, the C5-T1 ventral rami are delineated, continuing caudally and laterally between the middle and anterior scal
Regional nodal irradiation; left sided
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Left sided; 25 Gy if regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Left sided; 15 Gy if RNI
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Left sided.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Regional nodal irradiation; right sided
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Right sided; 25 Gy if regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Right sided; 15 Gy if RNI
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Right sided.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Heart/pericardium 60 Gy (15 cc), 40 Gy (20%), and 68 Gy (0.035 cc). <b>Contouring instructions<b>: "Contoured along with the pericardial sac; the superior aspect (or base) for purposes of contouring will begin at the level of the inferior aspect of the aortic arch (aorto-pulmonary window) and extend inferiorly to the apex of the heart."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Heart/pericardium 60 Gy (15 cc), 40 Gy (20%), and 68 Gy (0.035 cc). <b>Contouring instructions<b>: "Contoured along with the pericardial sac; the superior aspect (or base) for purposes of contouring will begin at the level of the inferior aspect of the aortic arch (aorto-pulmonary window) and extend inferiorly to the apex of the heart."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>QUANTEC!https://pubmed.ncbi.nlm.nih.gov/20171522/<ll>: V25 < 10% is associated with a < 1% probability of cardiac mortality at ~15 years after RT.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>QUANTEC!https://pubmed.ncbi.nlm.nih.gov/20171522/<ll>: V25 < 10% is associated with a < 1% probability of cardiac mortality at ~15 years after RT.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Includes regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
No regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Breast VMAT; Left sided
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Breast VMAT; Right sided
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Breast VMAT. Includes regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
LV and combined bilateral ventricles
Per a prospective evaluation on a RCT concerning forward-planned vs. inverse planned IMRT for breast cancer <ll>Abraham IJROBP '22!https://pubmed.ncbi.nlm.nih.gov/35085715/<ll>, maintaining the LV volume receiving 5 Gy and 10 Gy to < 42 cc and < 38 cc, respectively, can reduce the risk of radiation related late cardiac events at 10 years to < 5% over baseline.
Test
LV and combined bilateral ventricles
Per a prospective evaluation on a RCT concerning forward-planned vs. inverse planned IMRT for breast cancer <ll>Abraham IJROBP '22!https://pubmed.ncbi.nlm.nih.gov/35085715/<ll>, maintaining the LV volume receiving 5 Gy and 10 Gy to < 42 cc and < 38 cc, respectively, can reduce the risk of radiation related late cardiac events at 10 years to < 5% over baseline.
Test
Pay attention to the 15 Gy IDL! Per <ll>Atkins JAMA Onc '20!https://pubmed.ncbi.nlm.nih.gov/33331883/<ll> (NSCLC): LV V15 ≥ 1% increased risk among patients with CHD, with 1y MACE for LV V15 ± 1% of 4→ 8%. Optimal cut points for substructure and RT doses were LAD V15 ≥ 10% (C-index 0.64), L Cx V15 ≥ 14% (0.64), LV V15 ≥ 1% (0.64) and mean total coronary artery dose ≥ 7 Gy (0.62) in regard to association with MACE and mortality in NSCLC. Additional data from the 2022 Atkins group <ll>McKenzie IJR
----
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
----
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Key: * = Complementary/critical/cold minimum volume. CVxGy[cc] ≥ y (i.e., volume receiving x[Gy] or less is greater than y[cc]) per <ll>TG-263!https://www.aapm.org/pubs/reports/RPT_263.pdf<ll> (Figure 4, p.24).
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
----
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
----
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
No regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Includes regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
No regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Includes regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Includes regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
No regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Includes regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Includes regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Breast VMAT
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Breast VMAT
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Breast VMAT
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Breast VMAT
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
No regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Kaider-Person Clin Onc '18!https://doi.org/10.1016/j.clon.2017.11.004<ll>: Low rates of toxicity were discovered when Dmax of < 130 Gy were generally employed. With Dmax from 88-126 Gy range, there was low rates of G3+ ulceration (3-8%) .and fibrosis (10-16%). Hence, Dmax from 126-130 Gy to chest wall may be reasonable. However, these values were retrieved from small series, using various radiotherapy schedules, volumes and techniques, and with scarce information about toxicity. Moreover
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Regional nodal irradiation.
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
No regional nodal irradiation.
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Breast VMAT
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Breast VMAT
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Hotspots for 15 fractions defined as >105%, while >107% for conventional.
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
NSABP B-51: REQUIRED Compliance Criteria: Per Protocol: At least 95% of the Chestwall or Breast PTV Eval will receive 47.5 Gy which is 95% of the chestwall or breast prescribed dose of 50 Gy Variation Acceptable: At least 90% of the Chestwall or Breast PTV Eval will receive 45 Gy which is 90% of the whole breast prescribed dose of 50 Gy.
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
NSABP B-51: REQUIRED Compliance Criteria: Per Protocol: At least 95% of the Chestwall or Breast PTV Eval will receive 47.5 Gy which is 95% of the chestwall or breast prescribed dose of 50 Gy Variation Acceptable: At least 90% of the Chestwall or Breast PTV Eval will receive 45 Gy which is 90% of the whole breast prescribed dose of 50 Gy.
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
NSABP B-51: REQUIRED Compliance Criteria: Per Protocol: At least 95% of the Chestwall or Breast PTV Eval will receive 47.5 Gy which is 95% of the chestwall or breast prescribed dose of 50 Gy Variation Acceptable: At least 90% of the Chestwall or Breast PTV Eval will receive 45 Gy which is 90% of the whole breast prescribed dose of 50 Gy.
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
NSABP B-51: REQUIRED Compliance Criteria: Per Protocol: At least 95% of the Chestwall or Breast PTV Eval will receive 47.5 Gy which is 95% of the chestwall or breast prescribed dose of 50 Gy Variation Acceptable: At least 90% of the Chestwall or Breast PTV Eval will receive 45 Gy which is 90% of the whole breast prescribed dose of 50 Gy.
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
NSABP B-51: REQUIRED Compliance Criteria: Per Protocol: At least 95% of the Chestwall or Breast PTV Eval will receive 47.5 Gy which is 95% of the chestwall or breast prescribed dose of 50 Gy Variation Acceptable: At least 90% of the Chestwall or Breast PTV Eval will receive 45 Gy which is 90% of the whole breast prescribed dose of 50 Gy.
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
NSABP B-51: REQUIRED Compliance Criteria: Per Protocol: At least 95% of the Chestwall or Breast PTV Eval will receive 47.5 Gy which is 95% of the chestwall or breast prescribed dose of 50 Gy Variation Acceptable: At least 90% of the Chestwall or Breast PTV Eval will receive 45 Gy which is 90% of the whole breast prescribed dose of 50 Gy.
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
NSABP B-51: REQUIRED Compliance Criteria: Per Protocol: At least 95% of the Chestwall or Breast PTV Eval will receive 47.5 Gy which is 95% of the chestwall or breast prescribed dose of 50 Gy Variation Acceptable: At least 90% of the Chestwall or Breast PTV Eval will receive 45 Gy which is 90% of the whole breast prescribed dose of 50 Gy.
NSABP B-51 Per Protocol: At least 95% of the Axillary PTV will receive 47.5 Gy which is 95% of the prescribed dose of 50 Gy Variation Acceptable: At least 90% of the Axillary PTV will receive 45 Gy which is 90% of the prescribed dose of 50 Gy. Max point dose will be no more than 57.5 Gy which 115% of the prescription.
NSABP B-51: REQUIRED Compliance Criteria: Per Protocol: At least 95% of the Chestwall or Breast PTV Eval will receive 47.5 Gy which is 95% of the chestwall or breast prescribed dose of 50 Gy Variation Acceptable: At least 90% of the Chestwall or Breast PTV Eval will receive 45 Gy which is 90% of the whole breast prescribed dose of 50 Gy.
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
NSABP B-51 Per Protocol: At least 95% of the Axillary PTV will receive 47.5 Gy which is 95% of the prescribed dose of 50 Gy Variation Acceptable: At least 90% of the Axillary PTV will receive 45 Gy which is 90% of the prescribed dose of 50 Gy. Max point dose will be no more than 57.5 Gy which 115% of the prescription.
NSABP B-51 Per Protocol: At least 95% of the SCL PTV will receive 47.5 Gy which is 95% of the prescribed dose of 50 Gy Variation Acceptable: At least 90% of the SCL PTV will receive 45 Gy which is 90% of the prescribed dose of 50 Gy. Max point dose will be no more than 57.5 Gy which 115% of the prescription.
NSABP B-51: REQUIRED Compliance Criteria: Per Protocol: At least 95% of the Chestwall or Breast PTV Eval will receive 47.5 Gy which is 95% of the chestwall or breast prescribed dose of 50 Gy Variation Acceptable: At least 90% of the Chestwall or Breast PTV Eval will receive 45 Gy which is 90% of the whole breast prescribed dose of 50 Gy.
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
NSABP B-51 Per Protocol: At least 95% of the SCL PTV will receive 47.5 Gy which is 95% of the prescribed dose of 50 Gy Variation Acceptable: At least 90% of the SCL PTV will receive 45 Gy which is 90% of the prescribed dose of 50 Gy. Max point dose will be no more than 57.5 Gy which 115% of the prescription.
NSABP B-51 Per Protocol: At least 95% of the IMN PTV will receive 45 Gy which is 90% of the prescribed dose of 50 Gy Variation Acceptable: At least 90% of the IMN PTV will receive 40 Gy which is 80% of the prescribed dose of 50 Gy. Max point dose will be no more than 57.5 Gy which 115% of the prescription.
NSABP B-51: REQUIRED Compliance Criteria: Per Protocol: At least 95% of the Chestwall or Breast PTV Eval will receive 47.5 Gy which is 95% of the chestwall or breast prescribed dose of 50 Gy Variation Acceptable: At least 90% of the Chestwall or Breast PTV Eval will receive 45 Gy which is 90% of the whole breast prescribed dose of 50 Gy.
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
NSABP B-51 Per Protocol: At least 95% of the IMN PTV will receive 45 Gy which is 90% of the prescribed dose of 50 Gy Variation Acceptable: At least 90% of the IMN PTV will receive 40 Gy which is 80% of the prescribed dose of 50 Gy. Max point dose will be no more than 57.5 Gy which 115% of the prescription.
Per HN005 (OP): "The thyroid gland should be contoured in its entirety based on treatment planning CT scan. The thyroid gland has two connected lobes and is located inferior to the thyroid cartilage. The thyroid gland will have considerable contrast on contrast-enhanced CT compared to the surrounding tissues."
Per HN005 (OP): "The thyroid gland should be contoured in its entirety based on treatment planning CT scan. The thyroid gland has two connected lobes and is located inferior to the thyroid cartilage. The thyroid gland will have considerable contrast on contrast-enhanced CT compared to the surrounding tissues."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Less than 1 cm of heart in field if possible.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
*Heart (region location specific) < 5% to receive ≥ 5% (right breast);10% (excluding lower inner quadrant);15% (left lower inner quadrant location) of the prescribed dose
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Less than 1 cm of heart in field if possible.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Less than 2 cm strip of lung if possible.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Less than 2 cm strip of lung if possible.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Less than 2 cm strip of lung if possible.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Ipsi breast - PTV
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Ipsi breast - PTV
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Ipsi breast - PTV
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Per <ll>Florence!https://ascopubs.org/doi/full/10.1200/JCO.20.00650<ll>: Partial breast CTV defined as Clips + 1 cm (3 mm cropped from skin). Partial breast PTV defined as CTV + 1 cm, allowed 4 mm to lung and 3 mm from skin.
Per <ll>VA Blue Ribbon Panel!https://dx.doi.org/10.1016/j.prro.2022.05.005<ll> (Rectal Cancer): "With regard to short course treatment, the Blue-Ribbon Panel felt it was important to establish benchmark DVH constraints for quality control as there is sparse literature in regard to SCRT. The panel consensus for organ at risk (OAR) constraints included bladder constraints V15 ≤ 50%, V25 ≤ 20%, and Dmean ≤ 2000 cGy, femoral head constraint of D5% ≤ 2000 cGy and small bowel constraints (defined as i
Per <ll>Florence!https://ascopubs.org/doi/full/10.1200/JCO.20.00650<ll>: Partial breast CTV defined as Clips + 1 cm (3 mm cropped from skin). Partial breast PTV defined as CTV + 1 cm, allowed 4 mm to lung and 3 mm from skin.
Per <ll>Florence!https://ascopubs.org/doi/full/10.1200/JCO.20.00650<ll>: Partial breast CTV defined as Clips + 1 cm (3 mm cropped from skin). Partial breast PTV defined as CTV + 1 cm, allowed 4 mm to lung and 3 mm from skin.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Heart/pericardium 36.6 Gy (15 cc) and 42.5 Gy (0.035 cc). <b>Contouring instructions<b>: "Contoured along with the pericardial sac; the superior aspect (or base) for purposes of contouring will begin at the level of the inferior aspect of the aortic arch (aorto-pulmonary window) and extend inferiorly to the apex of the heart."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Lung 16 Gy (37%). Lung (minus GTV) minimum volume spared (MVS) from 15 Gy (males: 1500 cc*; females: 950 cc*). *One-third of "native" total organ volume (before any resection or volume reducing disease), whichever is greater. <b>Contouring instructions<b>: "Contour right and left lung as 1, structure including all parenchymal lung tissue but excluding the GTV and major airways (trachea and main/lobar bronchi)."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Ipsi breast - PTV
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Cord (and medulla) 39 Gy (5 cc) and 42 Gy (0.035 cc); <b>Cord contouring instructions<b>: "Entire bony canal including at least 10 cm superior and inferior to PTV." Brainstem (not medulla) 40 Gy (5 cc) and 44 Gy (0.035 cc); <b>Brainstem (not medulla) contouring instructions<b>: "Superiorly from incisura, midbrain and pons only, 1 structure."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Left sided
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Left sided, regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Left sided
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Left sided, no regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Left sided
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Right sided, regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Right sided, no regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Right sided
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Heart/pericardium 42 Gy (15 cc) and 48.9 Gy (0.035 cc). <b>Contouring instructions<b>: "Contoured along with the pericardial sac; the superior aspect (or base) for purposes of contouring will begin at the level of the inferior aspect of the aortic arch (aorto-pulmonary window) and extend inferiorly to the apex of the heart."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
No regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Heart/pericardium 42 Gy (15 cc) and 48.9 Gy (0.035 cc). <b>Contouring instructions<b>: "Contoured along with the pericardial sac; the superior aspect (or base) for purposes of contouring will begin at the level of the inferior aspect of the aortic arch (aorto-pulmonary window) and extend inferiorly to the apex of the heart."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Heart/pericardium 42 Gy (15 cc) and 48.9 Gy (0.035 cc). <b>Contouring instructions<b>: "Contoured along with the pericardial sac; the superior aspect (or base) for purposes of contouring will begin at the level of the inferior aspect of the aortic arch (aorto-pulmonary window) and extend inferiorly to the apex of the heart."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Heart/pericardium 42 Gy (15 cc) and 48.9 Gy (0.035 cc). <b>Contouring instructions<b>: "Contoured along with the pericardial sac; the superior aspect (or base) for purposes of contouring will begin at the level of the inferior aspect of the aortic arch (aorto-pulmonary window) and extend inferiorly to the apex of the heart."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Heart/pericardium 42 Gy (15 cc) and 48.9 Gy (0.035 cc). <b>Contouring instructions<b>: "Contoured along with the pericardial sac; the superior aspect (or base) for purposes of contouring will begin at the level of the inferior aspect of the aortic arch (aorto-pulmonary window) and extend inferiorly to the apex of the heart."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Heart/pericardium 42 Gy (15 cc) and 48.9 Gy (0.035 cc). <b>Contouring instructions<b>: "Contoured along with the pericardial sac; the superior aspect (or base) for purposes of contouring will begin at the level of the inferior aspect of the aortic arch (aorto-pulmonary window) and extend inferiorly to the apex of the heart."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
DBCG reportedly doesn't use this contraint anymore. Just contour heart, ensuring LAD in contour, and try to limit heart Dmax to 17-20 Gy.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Lung 18 Gy (37%). Lung (minus GTV) minimum volume spared (MVS) from 16.5 Gy (males: 1500 cc*; females: 950 cc*). *One-third of "native" total organ volume (before any resection or volume reducing disease), whichever is greater. <b>Contouring instructions<b>: "Contour right and left lung as 1, structure including all parenchymal lung tissue but excluding the GTV and major airways (trachea and main/lobar bronchi)."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Lung 18 Gy (37%). Lung (minus GTV) minimum volume spared (MVS) from 16.5 Gy (males: 1500 cc*; females: 950 cc*). *One-third of "native" total organ volume (before any resection or volume reducing disease), whichever is greater. <b>Contouring instructions<b>: "Contour right and left lung as 1, structure including all parenchymal lung tissue but excluding the GTV and major airways (trachea and main/lobar bronchi)."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Lung 18 Gy (37%). Lung (minus GTV) minimum volume spared (MVS) from 16.5 Gy (males: 1500 cc*; females: 950 cc*). *One-third of "native" total organ volume (before any resection or volume reducing disease), whichever is greater. <b>Contouring instructions<b>: "Contour right and left lung as 1, structure including all parenchymal lung tissue but excluding the GTV and major airways (trachea and main/lobar bronchi)."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Lung 18 Gy (37%). Lung (minus GTV) minimum volume spared (MVS) from 16.5 Gy (males: 1500 cc*; females: 950 cc*). *One-third of "native" total organ volume (before any resection or volume reducing disease), whichever is greater. <b>Contouring instructions<b>: "Contour right and left lung as 1, structure including all parenchymal lung tissue but excluding the GTV and major airways (trachea and main/lobar bronchi)."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Lung 18 Gy (37%). Lung (minus GTV) minimum volume spared (MVS) from 16.5 Gy (males: 1500 cc*; females: 950 cc*). *One-third of "native" total organ volume (before any resection or volume reducing disease), whichever is greater. <b>Contouring instructions<b>: "Contour right and left lung as 1, structure including all parenchymal lung tissue but excluding the GTV and major airways (trachea and main/lobar bronchi)."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Lung 18 Gy (37%). Lung (minus GTV) minimum volume spared (MVS) from 16.5 Gy (males: 1500 cc*; females: 950 cc*). *One-third of "native" total organ volume (before any resection or volume reducing disease), whichever is greater. <b>Contouring instructions<b>: "Contour right and left lung as 1, structure including all parenchymal lung tissue but excluding the GTV and major airways (trachea and main/lobar bronchi)."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Lung 18 Gy (37%). Lung (minus GTV) minimum volume spared (MVS) from 16.5 Gy (males: 1500 cc*; females: 950 cc*). *One-third of "native" total organ volume (before any resection or volume reducing disease), whichever is greater. <b>Contouring instructions<b>: "Contour right and left lung as 1, structure including all parenchymal lung tissue but excluding the GTV and major airways (trachea and main/lobar bronchi)."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Lung 18 Gy (37%). Lung (minus GTV) minimum volume spared (MVS) from 16.5 Gy (males: 1500 cc*; females: 950 cc*). *One-third of "native" total organ volume (before any resection or volume reducing disease), whichever is greater. <b>Contouring instructions<b>: "Contour right and left lung as 1, structure including all parenchymal lung tissue but excluding the GTV and major airways (trachea and main/lobar bronchi)."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Lung 18 Gy (37%). Lung (minus GTV) minimum volume spared (MVS) from 16.5 Gy (males: 1500 cc*; females: 950 cc*). *One-third of "native" total organ volume (before any resection or volume reducing disease), whichever is greater. <b>Contouring instructions<b>: "Contour right and left lung as 1, structure including all parenchymal lung tissue but excluding the GTV and major airways (trachea and main/lobar bronchi)."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
No regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Lung 18 Gy (37%). Lung (minus GTV) minimum volume spared (MVS) from 16.5 Gy (males: 1500 cc*; females: 950 cc*). *One-third of "native" total organ volume (before any resection or volume reducing disease), whichever is greater. <b>Contouring instructions<b>: "Contour right and left lung as 1, structure including all parenchymal lung tissue but excluding the GTV and major airways (trachea and main/lobar bronchi)."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
No regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Lung 18 Gy (37%). Lung (minus GTV) minimum volume spared (MVS) from 16.5 Gy (males: 1500 cc*; females: 950 cc*). *One-third of "native" total organ volume (before any resection or volume reducing disease), whichever is greater. <b>Contouring instructions<b>: "Contour right and left lung as 1, structure including all parenchymal lung tissue but excluding the GTV and major airways (trachea and main/lobar bronchi)."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>: Lung 18 Gy (37%). Lung (minus GTV) minimum volume spared (MVS) from 16.5 Gy (males: 1500 cc*; females: 950 cc*). *One-third of "native" total organ volume (before any resection or volume reducing disease), whichever is greater. <b>Contouring instructions<b>: "Contour right and left lung as 1, structure including all parenchymal lung tissue but excluding the GTV and major airways (trachea and main/lobar bronchi)."
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
No regional nodal irradiation.
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Per <ll>Timmerman IJROBP '21!https://doi.org/10.1016/j.ijrobp.2021.09.027<ll>:
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Hotspots for 15 fractions defined as >105%, while >107% for conventional.
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Regional nodal irradiation.
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
No regional nodal irradiation.
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>
Atlases: <ll>NRG!https://www.nrgoncology.org/ciro-breast<ll>, <ll>ESTRO!https://www.ncbi.nlm.nih.gov/pubmed/26791404<ll>, <ll>RADCOMP!https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx<ll>